Humulus lupulus L. Extract Prevents Ovariectomy-Induced Osteoporosis in Mice and Regulates Activities of Osteoblasts and Osteoclasts.
10.1007/s11655-019-2700-z
- Author:
Tian-Shuang XIA
1
;
Liu-Yue LIN
2
;
Qiao-Yan ZHANG
1
;
Yi-Ping JIANG
1
;
Chang-Hui LI
1
;
Xiao-Yan LIU
1
;
Lu-Ping QIN
3
;
Hai-Liang XIN
4
,
5
Author Information
1. Department of Pharmacognosy, School of Pharmacy, Second Military Medical University, Shanghai, (200433), China.
2. School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, (350108), China.
3. School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, (310053), China.
4. Department of Pharmacognosy, School of Pharmacy, Second Military Medical University, Shanghai, (200433), China. hailiangxin@
5. com.
- Publication Type:Journal Article
- Keywords:
Humulus lupulus L.;
osteoblasts;
osteoclasts;
osteoporosis;
ovariectomy-induced mice
- From:
Chinese journal of integrative medicine
2021;27(1):31-38
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To systematically evaluate the protective effects of Humulus lupulus L. extract (HLE) on osteoporosis mice.
METHODS:In vivo experiment, a total of 35 12-week-old female ICR mice were equally divided into 5 groups: the sham control group (sham); the ovariectomy with vehicle group (OVX); the OVX with estradiol valerate [EV, 0.2 mg/(kg•d)] the OVX with low- or high-dose HLE groups [HLE, 1 g/(kg•d) and 3 g/(kg•d)], 7 in each group. Treatment began 1 week after the ovariectomized surgery and lasted for 12 weeks. Bone mass and trabecular bone mircoarchitecture were evaluated by micro computed tomography, and bone turnover markers in serum were evaluated using enzyme-linked immunosorbent assay (ELISA) kits. In vitro experiment, osteoblasts and osteoclasts were treated with HLE at doses of 0, 4, 20 and 100 µg/mL. Biomarkers for bone formation in osteoblasts and bone resorption in osteoclasts were analyzed.
RESULTS:Compared with the OVX group, HLE exerted bone protective effects by the increase of estradiol (P<0.05), the improvement of cancellous bone structure, bone mineral density (P<0.01) and the reduction of serum alkaline phosphatase (ALP), tartrate resistant acid phosphatase (TRAP), bone gla-protein, c-terminal telopeptides of type I collagen (CTX-I) and deoxypyridinoline levels (P<0.01 for all). In vitro experiment, compared with the control group, HLE at 20 µg/mL promoted the cell proliferation (P<0.01), and increased the expression of bone morphogenetic protein-2 and osteopontin levels in osteoblasts (both P<0.05). HLE at 100 µg/mL increased the osteoblastic ALP activities, and HLE at all dose enhanced the extracellular matrix mineralization (both P<0.01). Furthermore, compared with the control group, HLE at 20 µg/mL and 100 µg/mL inhibited osteoclastic TRAP activity (P<0.01), and reduced the expression of matrix metalloproteinase-9 and cathepsin K (both P<0.05).
CONCLUSION:HLE may protect against bone loss, and have potentials in the treatment of osteoporosis.
